Skip to content
10-Q

Quarterly Report

Climb Bio, Inc. CLYM

0001193125-26-210357

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 57.26M sh
Shares Diluted Q1 2026 · Mar 31, 2026 68.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 67.46M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.38M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$15.43M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $8.36M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $35.69M
Stockholders Equity Q1 2026 · Mar 31, 2026 $148.09M
Stockholders Equity Q1 2026 · Dec 31, 2025 $160.48M
Stockholders Equity Q1 2026 · Mar 31, 2025 $193.39M
Stockholders Equity Q1 2026 · Dec 31, 2024 $211.88M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.07M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.98M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.29M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.27M
Current Assets Q1 2026 · Mar 31, 2026 $113.4M
Current Assets Q1 2026 · Dec 31, 2025 $105.85M
Total Assets Q1 2026 · Mar 31, 2026 $152.37M
Total Assets Q1 2026 · Dec 31, 2025 $167.74M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.20
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.31
Eps Basic Q1 2026 · Mar 31, 2026 −$0.20
Eps Basic Q1 2026 · Mar 31, 2025 −$0.31
Sga Expense Q1 2026 · Mar 31, 2026 $5.84M
Sga Expense Q1 2026 · Mar 31, 2025 $5.69M
Rd Expense Q1 2026 · Mar 31, 2026 $9.37M
Rd Expense Q1 2026 · Mar 31, 2025 $17.33M
Net Income Q1 2026 · Mar 31, 2026 −$13.72M
Net Income Q1 2026 · Mar 31, 2025 −$20.78M
Operating Income Q1 2026 · Mar 31, 2026 −$15.21M
Operating Income Q1 2026 · Mar 31, 2025 −$23.02M